The key question is what happens long-term
Interest in bioresorbable scaffolds endures despite an excess of adverse outcomes with the Absorb™ bioresorbable scaffold at year 2 of the ABSORB III trial reported at the American College of Cardiology meeting in March (detailed here). In this three-minute video, ABSORB III principal investigator and Cleveland Clinic cardiologist Stephen Ellis, MD, explains why the rationale behind bioresorbable scaffolds remains intact and that the key question is what happens with these devices over the long term.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
Advertisement
How our first century has impacted cardiovascular practice
Review offers comprehensive assessment of the landscape for wearables and more
Preserving trust in research requires vigilance and consensus around statistical nuances
Cardiac surgeon Patrick Vargo, MD, reflects on his first year as Cleveland Clinic staff
Improved risk prediction for patients is at the heart of Dr. Aaron Weiss’ research interests
Centralization would likely bring better outcomes, experts say, but may not be feasible
Dr. Daniel Burns on mentorship, robotic valve surgery, statistics and more
JACC review makes the case and outlines how to ensure oversight